Fortress Biotech Inc ( (FBIO) ) has released its Q3 earnings. Here is a breakdown of the information Fortress Biotech Inc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Journey Medical Corporation is a commercial-stage pharmaceutical company that specializes in selling and marketing FDA-approved prescription products for dermatological conditions. Based in Scottsdale, Arizona, the company is known for its efficient sales and marketing model and its portfolio of eight branded prescription drugs.
In the third quarter of 2025, Journey Medical Corporation reported net revenues of $17.6 million, marking a 21% increase from the previous year. The company’s growth was significantly driven by its product Emrosi™, which saw a 146% increase in total prescriptions and generated $4.9 million in net sales. The company also highlighted the clinical differentiation of Emrosi, which was validated through a Phase 3 efficacy analysis.
Key financial metrics for the quarter included a gross margin of 67.4%, slightly lower than the previous year’s 69.4% due to one-time non-operational adjustments in 2024. Selling, general, and administrative expenses rose by 6% to $12.1 million, primarily due to the launch and commercialization of Emrosi. The company reported a net loss of $2.3 million, an improvement from the $2.4 million loss in the same quarter of the previous year. Notably, Adjusted EBITDA improved to $1.7 million from $0.3 million in the prior year.
Journey Medical’s recent corporate highlights include expanded payer access for Emrosi, now covering over 100 million commercial lives in the U.S., and the presentation of efficacy data at a major dermatology conference. The company’s cash and cash equivalents increased to $24.9 million as of September 30, 2025, up from $20.3 million at the end of 2024.
Looking ahead, Journey Medical’s management remains optimistic about the continued growth of Emrosi and its established dermatology commercial infrastructure, which they believe will generate significant operating leverage. The company is poised to strengthen its position in the dermatology market with its innovative products and strategic initiatives.